924 studies found for:    "Stomach carcinoma"
Show Display Options
Rank Status Study
1 Not yet recruiting Labeled PET in Studying Patients With Gastric Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage IA Gastric Cancer;   Stage IB Gastric Cancer;   Stage IIA Gastric Cancer;   Stage IIB Gastric Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Gastric Cancer
Interventions: Radiation: copper Cu 64-DOTA-trastuzumab;   Device: positron emission tomography;   Other: laboratory biomarker analysis
2 Terminated A Phase I/II Study of Genasense (G3139) in Combination With Cisplatin and Fluorouracil in Patients With Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Biological: oblimersen sodium;   Other: laboratory biomarker analysis;   Drug: cisplatin;   Drug: fluorouracil
3 Completed A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2
Conditions: Stomach Neoplasms;   Cancer of Stomach;   Cancer of the Stomach;   Gastric Cancer;   Gastric Neoplasms
Intervention: Drug: ASLAN001
4 Recruiting Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Squamous Cell Carcinoma of the Esophagus;   Stage IA Esophageal Cancer;   Stage IA Gastric Cancer;   Stage IB Esophageal Cancer;   Stage IB Gastric Cancer;   Stage IIA Esophageal Cancer;   Stage IIA Gastric Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer
Interventions: Biological: bevacizumab;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
5 Completed S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer
Conditions: Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage III Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis
6 Completed Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
Conditions: Adenocarcinoma of the Stomach;   Stage II Gastric Cancer;   Stage III Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: irinotecan hydrochloride;   Drug: cisplatin;   Procedure: conventional surgery;   Procedure: positron emission tomography/computed tomography;   Radiation: fludeoxyglucose F 18;   Other: fluorine F 18 fluorothymidine
7 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: DEC-205-NY-ESO-1 fusion protein vaccine;   Drug: sirolimus;   Other: laboratory biomarker analysis
8 Recruiting Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, and Urologic Cancers
Conditions: Healthy, no Evidence of Disease;   Localized Transitional Cell Cancer of the Renal Pelvis and Ureter;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Psychosocial Effects of Cancer and Its Treatment;   Recurrent Bladder Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Uterine Sarcoma;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage II Bladder Cancer;   Stage II Renal Cell Cancer;   Stage II Urethral Cancer;   Stage IIA Cervical Cancer;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Cervical Cancer;   Stage IIB Colon Cancer;   Stage IIB Gastric Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Colon Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Bladder Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage III Urethral Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Cervical Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IV Urethral Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Cervical Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Stage IVB Uterine Sarcoma;   Ureter Cancer
Interventions: Other: educational intervention;   Behavioral: telephone-based intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
9 Completed Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: irinotecan hydrochloride;   Biological: bevacizumab;   Drug: cisplatin;   Procedure: computed tomography;   Other: laboratory biomarker analysis
10 Completed Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: capecitabine
11 Active, not recruiting
Has Results
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: alvocidib;   Drug: irinotecan hydrochloride;   Other: laboratory biomarker analysis
12 Completed Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Recurrent Gastric Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: sorafenib tosylate;   Drug: docetaxel;   Drug: cisplatin
13 Terminated EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
Conditions: Advanced Adult Primary Liver Cancer;   Carcinoma of the Appendix;   Fallopian Tube Cancer;   Gastrointestinal Stromal Tumor;   Localized Extrahepatic Bile Duct Cancer;   Localized Gallbladder Cancer;   Localized Gastrointestinal Carcinoid Tumor;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Sarcoma;   Ovarian Stromal Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Colon Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Small Intestine Cancer;   Recurrent Uterine Sarcoma;   Regional Gastrointestinal Carcinoid Tumor;   Small Intestine Adenocarcinoma;   Small Intestine Leiomyosarcoma;   Small Intestine Lymphoma;   Stage 0 Non-small Cell Lung Cancer;   Stage I Adult Soft Tissue Sarcoma;   Stage I Colon Cancer;   Stage I Gastric Cancer;   Stage I Non-small Cell Lung Cancer;   Stage I Ovarian Epithelial Cancer;   Stage I Ovarian Germ Cell Tumor;   Stage I Pancreatic Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage II Colon Cancer;   Stage II Gastric Cancer;   Stage II Non-small Cell Lung Cancer;   Stage II Ovarian Epithelial Cancer;   Stage II Ovarian Germ Cell Tumor;   Stage II Pancreatic Cancer;   Stage II Rectal Cancer;   Stage II Uterine Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Colon Cancer;   Stage III Gastric Cancer;   Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Colon Cancer;   Stage IV Gastric Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Stage IV Uterine Sarcoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: EF5;   Drug: motexafin lutetium;   Other: pharmacological study
14 Recruiting A Study Comparing Billroth II With Roux-en-Y Reconstruction for Gastric Cancer
Conditions: Gastric Cancer;   Stomach Cancer;   Gastrectomy
Intervention: Procedure: Roux-en-Y or Billroth II
15 Active, not recruiting Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
Conditions: Gastric Cancer;   Stomach Cancer
Intervention: Drug: Cetuximab/ Irinotecan/ Cisplatin
16 Not yet recruiting Endoscopic Ultrasonographic Staging and Conventional Endoscopic Staging for Depth of Invasion for Early Gastric Cancer
Conditions: Gastric Tumor;   Early Gastric Cancer
Intervention:
17 Active, not recruiting A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Conditions: HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma;   HER2 + Breast Cancer;   HER2 + Gastric Cancer;   Squamous Cell Carcinoma of Head and Neck;   Esophageal Squamous Cell Carcinoma
Intervention: Drug: LJM716
18 Active, not recruiting Combination Chemotherapy With or Without GDC-0449 in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage III Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: FOLFOX regimen;   Drug: vismodegib;   Other: hydrocortisone/placebo;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: flow cytometry;   Other: enzyme-linked immunosorbent assay;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis
19 Completed Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage III Esophageal Cancer;   Stage III Gastric Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIC Esophageal Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: saracatinib;   Other: laboratory biomarker analysis
20 Terminated Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IV Breast Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: Akt inhibitor MK2206;   Biological: trastuzumab;   Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years